Results 251 to 260 of about 1,075,360 (295)

Metagenes Associated with Survival in Non-Small Cell Lung Cancer

Cancer Informatics, 2011
Egon Urgard, Tõnu Vooder, Urmo Võsa, Kristjan Välk, Mingming Liu, Cheng Luo, Fabian Hoti, Retlav Roosipuu, Tarmo Annilo, Jukka Laine, Christopher M. Frenz, Liqing Zhang, Andres Metspalu   +12 more
doaj  

Some of the next articles are maybe not open access.

Related searches:

Non–Small Cell Lung Cancer

Journal of the National Comprehensive Cancer Network, 2008
Lung cancer is the leading cause of cancer-related death in both men and women in the United States. An estimated 213,380 new cases (114,760 men and 98,620 women) of lung and bronchus cancer will be diagnosed in 2007, and 160,390 deaths (89,510 in men, 70,880 in women) are estimated to occur because of the disease.
David S, Ettinger, Wallace, Akerley, Gerold, Bepler, Andrew, Chang, Richard T, Cheney, Lucian R, Chirieac, Thomas A, D'Amico, Todd L, Demmy, Steven J, Feigenberg, Robert A, Figlin, Ramaswamy, Govindan, Frederic W, Grannis, Thierry, Jahan, Mohammad, Jahanzeb, Anne, Kessinger, Ritsuko, Komaki, Mark G, Kris, Corey J, Langer, Quynh-Thu, Le, Renato, Martins, Gregory A, Otterson, Jyoti D, Patel, Francisco, Robert, David J, Sugarbaker, Douglas E, Wood   +24 more
  +9 more sources

Non-small-cell lung cancer

The Lancet, 2011
In the decade since the last Lancet Seminar on lung cancer there have been advances in many aspects of the classification, diagnosis, and treatment of non-small-cell lung cancer (NSCLC). An international panel of experts has been brought together to focus on changes in the epidemiology and pathological classification of NSCLC, the role of CT screening ...
Peter, Goldstraw, David, Ball, James R, Jett, Thierry, Le Chevalier, Eric, Lim, Andrew G, Nicholson, Frances A, Shepherd   +6 more
openaire   +3 more sources

Non-small-cell lung cancer

Nature Reviews Disease Primers
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screening of populations at risk with low-dose CT, the implementation of novel surgical and ...
Lizza E. L. Hendriks, Jordi Remon, Corinne Faivre-Finn, Marina C. Garassino, John V. Heymach, Keith M. Kerr, Daniel S. W. Tan, Giulia Veronesi, Martin Reck   +8 more
  +6 more sources

Non-small cell lung cancer

Current Problems in Cancer, 1987
Lung cancer stands as the most important malignant neoplasm in the United States because of its high prevalence, increasing incidence, high rate of mortality, and great potential for prevention through the control of cigarette smoking. The World Health Organization (WHO) classification of lung cancer identifies four major types: squamous cell carcinoma,
C M, Haskell, E C, Holmes
openaire   +3 more sources

Advanced non-small cell lung cancer

Current Treatment Options in Oncology, 2001
The treatment of advanced non-small cell lung cancer requires histologic proof of diagnosis, careful staging, and assessment of each patient's performance status and comorbidities. For patients with stage IIIB (pleural effusion) and stage IV disease who have a Cancer and Leukemia Group B performance status (PS) of 0 to 1, appropriate management ...
M J, Edelman, S L, Khanwani
openaire   +2 more sources

Synchronous non-small cell lung cancers

The American Journal of Surgery, 1996
The few series of synchronous lung cancers have included small cell and carcinoid tumors. We wished to determine the prognosis for patients with synchronous non-small cell lung cancer (NSCLC).A database of 3034 lung cancer patients was reviewed for synchronous NSCLC. Survival was determined by Kaplan-Meier method and compared by log-rank analysis.There
R F, Pommier, J T, Vetto, J T, Lee, K M, Johnston   +3 more
openaire   +2 more sources

Bevacizumab in Non-Small Cell Lung Cancer

Drugs, 2008
Lung cancer continues to be the leading cause of cancer death in Western countries. The median survival time for advanced non-small cell lung cancer (NSCLC) remains poor and chemotherapy is the treatment of choice for most patients with metastatic NSCLC. Platinum-based chemotherapy has long been the standard of care for advanced NSCLC. The formation of
Di Costanzo F., Mazzoni F., Micol Mela M., Antonuzzo L., Checcacci D., Saggese M., Di Costanzo F.   +6 more
openaire   +2 more sources